Independent Business Valuation
DCF and market multiples applied to the entity as it actually operates, not as the seller presents it.
Valuations & Fairness Opinions
In healthcare M&A, a valuation is only as strong as the case built behind it.
A valuation is a number you can defend in a negotiation, a boardroom, or a court, or it is a wish. We build ours from the drivers a counterparty will actually test, payer mix and licence transferability, weighed against the quality of the numbers behind them, and we disclose the method before we run the model. The result is a range you can hand to the other side's advisor and still stand behind.
Who engages this
Owners preparing to sell a clinic, hospital group, or pharma asset in the UAE and wider GCC. Boards commissioning a fairness opinion ahead of a related-party or control transaction. Shareholders in a dispute or a buyout, where the valuation determines what one side pays the other. Private equity marking a position at year-end or pricing an exit. Families dividing ownership between siblings or generations, where the number has to be right for everyone at the table, not just the party who commissioned it.
The work
What this practice takes on.
Hospital & Clinic Group Valuation
Payer mix, licence transferability, and clinical staff retention priced into the range, not footnoted around it.
Pharma Asset Valuation
Royalty relief and comparable-transaction methods for registered products, pipeline assets, and distribution rights.
Fairness Opinions
An independent view for the board on a related-party, control, or squeeze-out transaction, built to withstand challenge.
Shareholder-Exit & Dispute Valuation
A defensible number for a buyout, a divorce, or a falling-out between partners, prepared for adversarial review.
Purchase Price Allocation
Post-close allocation of consideration across tangible assets, licences, and goodwill for audit and tax purposes.
Pre-IPO & Pre-Raise Valuation Readiness
The valuation narrative and supporting model built before you face investors, not assembled after their first question.
Second Opinions on Existing Valuations
An independent review of a valuation prepared by the other side's advisor, before you rely on it.
On a mandate
Two brothers who jointly owned a Sharjah clinic group disagreed on a buyout price for the one who wanted out; each held a valuation from his own advisor, a difference of 40%. We were engaged jointly and rebuilt the model from source data: normalised owner compensation, tested payer concentration, and separated one under-licensed satellite clinic into its own line. The resulting range let the brothers settle within three weeks, at a figure inside our band.
Questions
What clients ask first.
What method do you use to value a healthcare business?
It depends on the asset. Operating clinics and hospital groups are usually valued on discounted cash flow, cross-checked against trading and precedent-transaction multiples for comparable regional assets. Pharma products and pipeline assets typically call for royalty relief, since the value sits in a licensed right to a future revenue stream rather than in current operating cash flow. We select and disclose the method before we run the numbers, not after we see which one produces the bigger figure.
Can you just tell me what my business is worth?
We give you a base, upside, and downside range with the drivers labelled, payer mix and licence transferability chief among them, weighed against the quality of the underlying numbers, never a single point figure. A single number invites the question of what assumption produced it; a labelled range answers that question before it is asked.
How long does an independent valuation take?
Ten to fifteen business days for a single entity, twenty to thirty for a group, and twenty-five to thirty-five for a pharmaceutical asset. Compressing that timeline means compressing the diligence behind the number, which is the part that has to hold up later.
Will a valuation you prepare hold up if challenged by the other side?
That is the standard we build to. Every valuation states its method, its assumptions, and its sources, so it can be handed to an opposing advisor, a court, or a regulator and defended line by line, not just presented and hoped past.
If you need a number you can stand behind, start with a conversation with a principal.